Efficacy of a Low-threshold, Culturally-Sensitive Group Psychoeducation Programme for Asylum Seekers (LoPe): study protocol for a multicentre randomised controlled trial

Autor: Carmen Schade-Brittinger, Jens-Peter Reese, Nexhmedin Morina, Ricarda Mewes, Cornelia Weise, Freyja Grupp, Thomas Ehring, Ulrich Stangier, Regina Steil, Johannes Johow

Publikováno v: BMJ Open, Vol 11, Iss 10 (2021)

Introduction Despite high levels of mental distress, accessing psychological treatment is difficult for asylum seekers in Western host countries due to a lack of knowledge about mental disorders, and the health system, as well as due to cultural and

Externí odkaz: https://doaj.org/article/96f354d326644cb9ad2b884c89af708b

When the mother-in-law is just as good-Differential mortality of reproductive females by family network composition.

Autor: Kai Pierre Willführ, Johannes Johow, Eckart Voland

Publikováno v: PLoS ONE, Vol 13, Iss 3, p e0193252 (2018)

Motivated by the cooperative breeding hypothesis, we investigate the effect of having kin on the mortality of reproductive women based on family reconstitutions for the Krummhörn region (East Frisia, Germany, 1720-1874). We rely on a combination of

Externí odkaz: https://doaj.org/article/5b10bf484b7e4afbaa2e8dec60ac93b8

The structured delegation of medical care services for patients with inflammatory rheumatic diseases

Autor: Dietmar Krause, Anna Mai, Robin Denz, Johannes Johow, Jens-Peter Reese, Benjamin Westerhoff, Renate Klaaßen-Mielke, Nina Timmesfeld, Annette Rittstieg, Ertan Saracbasi-Zender, Judith Günzel, Claudia Klink, Elmar Schmitz, Claas Fendler, Wolf Raub, Stephanie Böddeker, Friedrich Dybowski, Georg Hübner, Hans-Jürgen Menne, Heinz-Jürgen Lakomek, Michael Sarholz, Ulrike Trampisch, Hans J. Trampisch, Jürgen Braun

Publikováno v: Deutsches Ärzteblatt international.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21773e727b997ed1cbc3c562d741df2e
https://doi.org/10.3238/arztebl.m2022.0109

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF) : A double-blind, randomised, placebo-controlled, phase 2b trial

Autor: Jürgen Behr, Antje Prasse, Michael Kreuter, Johannes Johow, Klaus F Rabe, Francesco Bonella, Reiner Bonnet, Christian Grohe, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H Ficker, Wolfgang Neumeister, Nicolas Schönfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Günther, Nicolaus Schönfeld, Carmen Schade-Brittinger, Behnaz Aminossadati, Christian Nasemann, Soraya Yahiaoui, Christoph Dupuy Backofen, Maik Hahmann, Michael Wittenberg, Fotis Drakopanagiotakis, Daniel von der Beck, Stefanie Ghofrani, Sabine Heinemann, Ekaterina Krauss, Hella Rethorn, Andrea Koch, Gabriela Leuschner, Sandhya Matthes, Claus Neurohr, Tobias Veit, Katrin Milger-Kneidinger, Felix Herth, Julia Benstz, Thomas Bahmer, Heike Biller, Benjamin Waschki, Rosa-Marie Apel, Ulrich Costabel, Eva Börner, Thomas Wessendorf, Margret Arnrich, Lacramioara Ilie, Alexandra Wald, Hans-Jürgen Seyfarth, Christian Reinhardt, Atif Cinar, Markus Vogler, Siegfried Matthias Huhn, Jaqueline Richter, Ulrich Neff, Torsten Gerriet Blum, Silvan Vesenbeckh, Christian Boch, Hannes Semper, Andreas Wilke, Michael Pfeifer, Annette Schweda, Angelika Krill, Christian Lensch, Franziska Joa, Barbara Schröder, Annabel Plaßmeier, Stefan Baron, Klaus Peter Froehling

Publikováno v: Lancet Resp. Med. 9, 476-486 (2021)

Methods We did a multicentre, double-blind, randomised, placebo-controlled, parallel phase 2b trial (RELIEF) in 17 centres with expertise in ILD in Germany. Eligible participants were patients aged 18?80 years with progressive fibrotic ILD due to fou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4b6327b7d6687b4291da21ef340b24
https://www.ncbi.nlm.nih.gov/pubmed/33798455

Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Autor: Johannes Johow, Joachim Hoyer, Claus Vogelmeier, Hinnerk Wulf, Thomas Wiesmann, Caroline Rolfes, Elisabeth Mack, Ralf Michael Muellenbach, Christian Keller, Andreas Neubauer, Carmen Schade-Brittinger, Iuliu Torje, Chrysanthi Skevaki, Andrea Kadlubiec, Damaris Meyn, Andreas Burchert

Publikováno v: Leukemia

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 (coronavirus disease 2019), which is associated with high morbidity and mortality, especially in elder patients. Acute respiratory distress syndrome (ARDS) is a life-threate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b668ae3ce8b52058d9f0ae5eb91c6e
http://europepmc.org/articles/PMC8436193